All patients
HER2 positive
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
breast cancer - HER2-positive, HER inhibitor vs. ..., meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.62 [0.30; 1.27]
0.62 [0.30 ; 1.27 ] NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 1 0% 301 NA not evaluable deaths (OS) (extension)detailed results NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.72 [0.41; 1.27]
NeoALTTO (lapatinib vs trastuzumab), 2012 0.85 [0.49; 1.47]
0.78 [0.53 ; 1.16 ] NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012, NeoALTTO (lapatinib vs trastuzumab), 2012 2 0% 604 moderate not evaluable events or deaths (EFS)detailed results NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.78 [0.47; 1.29]
0.78 [0.47 ; 1.29 ] NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 1 0% 301 NA not evaluable events or deaths (EFS) (extended)detailed results NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.81 [0.52; 1.26]
NeoALTTO (lapatinib vs trastuzumab), 2012 0.98 [0.64; 1.51]
0.89 [0.66 ; 1.22 ] NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012, NeoALTTO (lapatinib vs trastuzumab), 2012 2 0% 604 moderate not evaluable pCR detailed results NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 2.60 [1.49; 4.54]
NeoALTTO (lapatinib vs trastuzumab), 2012 0.78 [0.47; 1.30]
1.42 [0.44 ; 4.60 ] NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012, NeoALTTO (lapatinib vs trastuzumab), 2012 2 90% 604 moderate not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 02:12 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 336,147,145,355,337,146,317
- treatments: 712,429,903,472,969,902,1321,643,641,640,427,910,430,976,909,966,917,1013,1025,916,977,1029,1017,911,428,971,913,912,918,965,1067,978,915,914,973,974,702,1313,498,1314,368,1301,1412,1298,1299,1334,1332,1303,1325,1320,1305,1300,1429,1324,1335,1307,1322,1319,718,422,1304,421,1312,1326,1368,1373,1309,1302,1308